tbuckley/cabot-search huggingface dataset:
Effect of a Novel Mindfulness Curriculum on Burnout During Pediatric Internship
Authors: Yarden S. Fraiman, Christine C. Cheston, Howard J. Cabral, Celeste Allen, Andrea G. Asnes, Jefferson T. Barrett, Maneesh Batra, William Bernstein, Tammy Bleeker, Pam M. Dietz, Joanna Lewis, Su-Ting T. Li, T. Marsha Ma, John D. Mahan, Catherine D. Michelson, Sue E. Poynter, Mark A. Vining, Katherine Watson, Colin M. Sox
Journal: JAMA Pediatrics (2022)

Mindfulness curricula can improve physician burnout, but implementation during residency presents challenges.To examine whether a novel mindfulness curriculum implemented in the first 6 months of internship reduces burnout.This pragmatic, multicenter, stratified cluster randomized clinical trial of a mindfulness curriculum randomized 340 pediatric interns to the intervention or control arm within program pairs generated based on program size and region. Fifteen US pediatric training programs participated from June 14, 2017, to February 28, 2019.The intervention included 7 hour-long sessions of a monthly mindfulness curriculum (Mindfulness Intervention for New Interns) and a monthly mindfulness refresher implemented during internship. The active control arm included monthly 1-hour social lunches.The primary outcome was emotional exhaustion (EE) as measured by the Maslach Burnout Inventory 9-question EE subscale (range, 7-63; higher scores correspond to greater perceived burnout). Secondary outcomes were depersonalization, personal accomplishment, and burnout. The study assessed mindfulness with the Five Facet Mindfulness Questionnaire and empathy with the Interpersonal Reactivity Index subscales of perspective taking and empathetic concern. Surveys were implemented at baseline, month 6, and month 15.Of the 365 interns invited to participate, 340 (93.2%; 255 [75.0%] female; 51 [15.0%] 30 years or older) completed surveys at baseline; 273 (74.8%) also participated at month 6 and 195 (53.4%) at month 15. Participants included 194 (57.1%) in the Mindfulness Intervention for New Interns and 146 (42.9%) in the control arm. Analyses were adjusted for baseline outcome measures. Both arms' EE scores were higher at 6 and 15 months than at baseline, but EE did not significantly differ by arm in multivariable analyses (6 months: 35.4 vs 32.4; adjusted difference, 3.03; 95% CI, -0.14 to 6.21; 15 months: 33.8 vs 32.9; adjusted difference, 1.42; 95% CI, -2.42 to 5.27). None of the 6 secondary outcomes significantly differed by arm at month 6 or month 15.A novel mindfulness curriculum did not significantly affect EE, burnout, empathy, or mindfulness immediately or 9 months after curriculum implementation. These findings diverge from prior nonrandomized studies of mindfulness interventions, emphasizing the importance of rigorous study design and suggesting that additional study is needed to develop evidence-based methods to reduce trainee burnout.ClinicalTrials.gov Identifier: NCT03148626.
Reimagining pelvic lymph node dissection during radical prostatectomy: Insights from a large series of fluorescence-guided procedures
Authors: F. Claps, M. Ramirez-Backhaus, J.M. Mascaros, A. Gomez-Ferrer, J. Dominguez-Escrig, J. Marenco, A. Collado-Serra, J. Casanova, A. Calatrava, C. Trombetta, J. Rubio-Briones
Journal: European Urology (2021)
Preoperative drivers of persistent/recurring Lower Urinary Tract Syndroms (LUTS) after Holmium Laser Enucleation of the Prostate (HoLEP) - report from a single center cohort of 902 patients with long-term follow-up
Authors: P. Gild, M.W. Vetterlein, T.A. Ludwig, P. Marks, A. Soave, R. Dahlem, M. Fisch, M. Rink, C.P. Meyer, A. Becker
Journal: European Urology (2021)
Mirabegron inhibits neurogenic and α1-adrenergic human prostate smooth muscle contractions, with similar pharmacologic patterns as α1-blockers
Authors: R. Huang, Y. Liu, B. Li, R. Wang, A. Tamalunas, R. Waidelich, F. Strittmatter, C.G. Stief, M. Hennenberg
Journal: European Urology (2021)
Efficiency analysis of an increase of focal shock wave energy through an expanded number of shockwaves per session for treating urinary stones up to 2 cm with extracorporeal shockwave lithotripsy
Authors: J.D. López-Acón, J. Díaz-Carnicero, A. Budía Alba, D.G. Ordaz-Jurado, P. Bahilo-Mateu, D. Vivas-Consuelo, F. Boronat-Tormo
Journal: European Urology (2021)
Prospective evaluation of erectile dysfunction with a validated patient reported outcome measure in patients with Peyronie’s disease requiring Nesbit’s type surgery
Authors: M. Skrodzka, D. Akiboye, J. Harrison, S. Yan, M. Natarajan, E. Anastasiadis, P. Patel, B. Ayres, N. Watkin
Journal: European Urology (2021)
Are corticosteroid creams and ointments linked with type 2 diabetes?
Journal: British Journal of Dermatology (2020)

Cosrtiocosteroids, such as prednisone and dexamethasone, are a common treatment for many skin issues.People who take these medicines by mouth are at greater risk of developing type 2 diabetes.It is not clear whether absorption of corticosteroid from creams or ointments also carries this risk.A recent study found a potential risk of using corticosteroid creams and developing type 2 diabetes.
Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Authors: Masashi Akiyama, Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Norio Okada, Takayuki Okuji, Takeshi Onoue, Motomitsu Goto, Mariko Sugiyama, Taku Tsunekawa, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Kenji Yokota, Tetsunari Hase, Naozumi Hashimoto, Masahiko Ando, Yasushi Fujimoto, Hideharu Hibi, Michihiko Sone, Yuichi Ando, Hiroshi Arima
Journal: Journal for ImmunoTherapy of Cancer (2020)
Factors associated with additional tumour-bearing lymph nodes at completion ILND after positive DSNB for penile cancer staging: A European multicentre evaluation
Authors: H.M. De Vries, H.J. Lee, E. Roussel, B. Kroon, I.J. De Jong, M. Albersen, A. Muneer, V. Sangar, A. Parnham, B. Ayres, N. Watkin, S. Horenblas, M.M. Stuiver, O.R. Brouwer
Journal: European Urology (2021)
Quality of facility-based maternal and newborn care around the time of childbirth during the COVID-19 pandemic: online survey investigating maternal perspectives in 12 countries of the WHO European Region
Authors: Marzia Lazzerini, Benedetta Covi, Ilaria Mariani, Zalka Drglin, Maryse Arendt, Ingvild Hersoug Nedberg, Helen Elden, Raquel Costa, Daniela Drandić, Jelena Radetić, Marina Ruxandra Otelea, Céline Miani, Serena Brigidi, Virginie Rozée, Barbara Mihevc Ponikvar, Barbara Tasch, Sigrun Kongslien, Karolina Linden, Catarina Barata, Magdalena Kurbanović, Jovana Ružičić, Stephanie Batram-Zantvoort, Lara Martín Castañeda, Elise de La Rochebrochard, Anja Bohinec, Eline Skirnisdottir Vik, Mehreen Zaigham, Teresa Santos, Lisa Wandschneider, Ana Canales Viver, Amira Ćerimagić, Emma Sacks, Emanuelle Pessa Valente
Journal: The Lancet Regional Health - Europe (2021)

Multi-country studies assessing the quality of maternal and newborn care (QMNC) during the COVID-19 pandemic, as defined by WHO Standards, are lacking.Women who gave birth in 12 countries of the WHO European Region from March 1, 2020 - March 15, 2021 answered an online questionnaire, including 40 WHO Standard-based Quality Measures.21,027 mothers were included in the analysis. Among those who experienced labour (N=18,063), 41·8% (26·1%- 63·5%) experienced difficulties in accessing antenatal care, 62% (12·6%-99·0%) were not allowed a companion of choice, 31·1% (16·5%-56·9%) received inadequate breastfeeding support, 34·4% (5·2%-64·8%) reported that health workers were not always using protective personal equipment, and 31·8% (17·8%-53·1%) rated the health workers' number as "insufficient". Episiotomy was performed in 20·1% (6·1%-66·0%) of spontaneous vaginal births and fundal pressure applied in 41·2% (11·5% -100%) of instrumental vaginal births. In addition, 23·9% women felt they were not treated with dignity (12·8%-59·8%), 12·5% (7·0%-23·4%) suffered abuse, and 2·4% (0·1%-26·2%) made informal payments. Most findings were significantly worse among women with prelabour caesarean birth (N=2,964). Multivariate analyses confirmed significant differences among countries, with Croatia, Romania, Serbia showing significant lower QMNC Indexes and Luxemburg showing a significantly higher QMNC Index than the total sample. Younger women and those with operative births also reported significantly lower QMNC Indexes.Mothers reports revealed large inequities in QMNC across countries of the WHO European Region. Quality improvement initiatives to reduce these inequities and promote evidence-based, patient-centred respectful care for all mothers and newborns during the COVID-19 pandemic and beyond are urgently needed.The study was financially supported by the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy.ClinicalTrials.gov Identifier: NCT04847336.
Association of Arterial Hyperoxia With Outcomes in Critically Ill Children
Authors: Thijs A. Lilien, Nina S. Groeneveld, Faridi van Etten-Jamaludin, Mark J. Peters, Corinne M. P. Buysse, Shawn L. Ralston, Job B. M. van Woensel, Lieuwe D. J. Bos, Reinout A. Bem
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Oxygen supplementation is a cornerstone treatment in pediatric critical care. Accumulating evidence suggests that overzealous use of oxygen, leading to hyperoxia, is associated with worse outcomes compared with patients with normoxia. <h3>Objectives</h3> To evaluate the association of arterial hyperoxia with clinical outcome in critically ill children among studies using varied definitions of hyperoxia. <h3>Data Sources</h3> A systematic search of EMBASE, MEDLINE, Cochrane Library, and ClinicalTrials.gov from inception to February 1, 2021, was conducted. <h3>Study Selection</h3> Clinical trials or observational studies of children admitted to the pediatric intensive care unit that examined hyperoxia, by any definition, and described at least 1 outcome of interest. No language restrictions were applied. <h3>Data Extraction and Synthesis</h3> The Meta-analysis of Observational Studies in Epidemiology guideline and Newcastle-Ottawa Scale for study quality assessment were used. The review process was performed independently by 2 reviewers. Data were pooled with a random-effects model. <h3>Main Outcomes and Measures</h3> The primary outcome was 28-day mortality; this time was converted to mortality at the longest follow-up owing to insufficient studies reporting the initial primary outcome. Secondary outcomes included length of stay, ventilator-related outcomes, extracorporeal organ support, and functional performance. <h3>Results</h3> In this systematic review, 16 studies (27 555 patients) were included. All, except 1 randomized clinical pilot trial, were observational cohort studies. Study populations included were post–cardiac arrest (n = 6), traumatic brain injury (n = 1), extracorporeal membrane oxygenation (n = 2), and general critical care (n = 7). Definitions and assessment of hyperoxia differed among included studies. Partial pressure of arterial oxygen was most frequently used to define hyperoxia and mainly by categorical cutoff. In total, 11 studies (23 204 patients) were pooled for meta-analysis. Hyperoxia, by any definition, showed an odds ratio of 1.59 (95% CI, 1.00-2.51; after Hartung-Knapp adjustment, 95% CI, 1.05-2.38) for mortality with substantial between-study heterogeneity (<i>I</i><sup>2</sup> = 92%). This association was also found in less heterogeneous subsets. A signal of harm was observed at higher thresholds of arterial oxygen levels when grouped by definition of hyperoxia. Secondary outcomes were inadequate for meta-analysis. <h3>Conclusions and Relevance</h3> These results suggest that, despite methodologic limitations of the studies, hyperoxia is associated with mortality in critically ill children. This finding identifies the further need for prospective observational studies and importance to address the clinical implications of hyperoxia in critically ill children.
TCT-404 ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-year results from a propensity score matched comparison
Authors: salvatore brugaletta, Tommaso Gori, Adrian Low, Petr Tousek, Eduardo Pinar Bermudez, Josep Gomez Lara, Luis Ortega-Paz, Eberhard Schulz, Mark Chan, Viktor Kocka, Jose Hurtado, Joan Antoni Gomez-Hospital, Thomas Muenzel, Chi-Hang Lee, Angel Cequier, Mariano Valdes, Petr Widimsky, Patrick Serruys, Manel Sabate
Journal: Journal of the American College of Cardiology (2016)
P13.18 Inhibition of epidermal growth factor receptor and platelet-derived growth factor receptor-alpha exerts synergistic efficacy in glioblastoma
Authors: E Noch, I Alnahhas, L Palma, L Cantley
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND Despite our understanding of the genetic changes that precipitate gliomagenesis, targeted therapy has failed in glioblastoma (GBM) with median survival not significantly improved over the past two decades. Epidermal growth factor receptor (EGFR) alterations, including amplification and activating mutations, are among the most common genetic changes in GBM, occurring in more than half of cases. EGFR is located on Chr. 7, and Chr. 7 gain is one of the earliest events precipitating gliomagenesis. Various EGFR inhibitors, including tyrosine kinase inhibitors, monoclonal antibodies, vaccines, and CAR-T cells have failed in GBM due to intrinsic heterogeneity and receptor tyrosine kinase bypass pathways that mediate therapeutic resistance. New targeted therapeutic approaches to leverage synergistic combinations are desperately needed to improve GBM prognosis. Using the TCGA and other GBM databases, we have previously demonstrated that the presence of PDGFRAamplification in patients with EGFR-amplified GBM carries significantly worse survival. EGFR and PDGFRA co-expression occur in more than one-third of GBM patients. The PDGFRA ligand PDGFA is also located on Chr. 7, and its expression is significantly increased with Chr. 7 gain and EGFR copy number increase. Therefore, Chr. 7 gain inherently leads to co-activation of both EGFR and PDGFRA signaling pathways. MATERIALS AND METHODS We used models of patient-derived glioblastoma cells to test combined inhibition of epidermal growth factor receptor and platelet-derived growth factor receptor-alpha in vitro. RESULTS Using patient-derived GBM models with Chr. 7 gain, we found that combined inhibition of both EGFR and PDGFRA using a variety of FDA-approved EGFR-targeted agents (Erlotinib, Gefitinib, Dacomitinib, Neratinib, and Osimertinib) and Crenolanib, respectively, leads to synergistic cytotoxicity in vitro. We found that inhibition of either EGFR or PDGFRA alone led to receptor cross-activation, and EGF and PDGF-AA-induced receptor tyrosine kinase activation was blocked by Neratinib and Crenolanib. Immunoprecipitation experiments and proximity ligation assays demonstrated that combined inhibition prevents EGFR and PDGFRA heterodimerization and pathways of therapeutic resistance. This combined inhibition led to decreased activation of downstream signaling pathways, including phosphatidylinositol 3-kinase and mitogen-activated protein kinase. CONCLUSIONS We show that combined inhibition of EGFR and PDGFRA exerts synergistic cytotoxicity in GBM and prevents resistance pathways that emerge during single-agent targeted therapy against these receptor tyrosine kinases. These pathways are targetable with FDA-approved agents that could be used in patients with GBM with Chr. 7 gain.
Error in Figure
Journal: JAMA Network Open (2021)

Alexander A. Brescia, MD, MSc; Tessa M. F. Watt, MD, MSc; Francis D. Pagani, MD, PhD; Thomas M. Cascino, MD, MSc; Min Zhang, PhD; Jeffrey S. McCullough, PhD; Supriya Shore, MD, MSc; Donald S. Likosky, PhD; Keith D. Aaronson, MD, MS; Michael P. Thompson, PhD; Michigan Congestive Heart Failure Investigators
Tryptophan 2,3-dioxygenase in tumor cells is associated with kynurenine accumulation and resistance to immunotherapy in renal cell carcinoma
Authors: M. Sumitomo, K. Zennami, K. Takahara, M. Takenaka, T. Nukaya, K. Fukaya, M. Ichino, H. Sasaki, R. Shiroki
Journal: European Urology (2021)
Feasibility of salvage robotic partial nephrectomy after ablative treatment failure (UroCCR-62 study)
Authors: G. Margue, M. Percot, L. Dupitout, C. Michiels, P. Blanc, E. Alezra, V. Estrade, G. Capon, F. Bladou, G. Robert, N. Grenier, J.C Bernhard
Journal: European Urology (2021)
Association between CEP72 genotype and persistent neuropathy in survivors of childhood acute lymphoblastic leukemia
Authors: Chelsea G. Goodenough, Barthelemy Diouf, Wenjian Yang, Yadav Sapkota, Emily R. Finch, Lu Lu, Robyn E. Partin, Matthew D. Wogksch, Melissa M. Hudson, Leslie L. Robison, Zhaoming Wang, Sima Jeha, William E. Evans, Kirsten K. Ness
Journal: Leukemia (2022)
Persistence of Long-COVID symptoms in a heterogenous prospective cohort
Authors: Chiara Mariani, Fabio Borgonovo, Amedeo F Capetti, Letizia Oreni, Maria Vittoria Cossu, Martina Pellicciotta, Luciana Armiento, Simona Bocchio, Gianfranco Dedivitiis, Angelica Lupo, Massimo Galli, Giuliano Rizzardini
Journal: Journal of Infection (2022)
Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia
Authors: Barbara Spitzer, Kayleigh D. Rutherford, Gunes Gundem, Erin M. McGovern, Nathan E. Millard, Juan E. Arango Ossa, Irene Y. Cheung, Teng Gao, Max F. Levine, Yanming Zhang, Juan S. Medina-Martínez, Yi Feng, Ryan N. Ptashkin, Kelly L. Bolton, Noushin Farnoud, Yangyu Zhou, Minal A. Patel, Georgios Asimomitis, Cassidy C. Cobbs, Neeman Mohibullah, Kety H. Huberman, Maria E. Arcilla, Brian H. Kushner, Shakeel Modak, Andrew L. Kung, Ahmet Zehir, Ross L. Levine, Scott A. Armstrong, Nai Kong V. Cheung, Elli Papaemmanuil
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Therapy-related myelodysplastic syndrome and acute leukemias (t-MDS/AL) are a major cause of nonrelapse mortality among pediatric cancer survivors. Although the presence of clonal hematopoiesis (CH) in adult patients at cancer diagnosis has been implicated in t-MDS/AL, there is limited published literature describing t-MDS/AL development in children. Experimental Design: We performed molecular characterization of 199 serial bone marrow samples from 52 patients treated for high-risk neuroblastoma, including 17 with t-MDS/AL (transformation), 14 with transient cytogenetic abnormalities (transient), and 21 without t-MDS/AL or cytogenetic alterations (neuroblastoma-treated control). We also evaluated for CH in a cohort of 657 pediatric patients with solid tumor. Results: We detected at least one disease-defining alteration in all cases at t-MDS/AL diagnosis, most commonly TP53 mutations and KMT2A rearrangements, including involving two novel partner genes (PRDM10 and DDX6). Backtracking studies identified at least one t-MDS/AL-associated mutation in 13 of 17 patients at a median of 15 months before t-MDS/AL diagnosis (range, 1.3–32.4). In comparison, acquired mutations were infrequent in the transient and control groups (4/14 and 1/21, respectively). The relative risk for development of t-MDS/AL in the presence of an oncogenic mutation was 8.8 for transformation patients compared with transient. Unlike CH in adult oncology patients, TP53 mutations were only detectable after initiation of cancer therapy. Last, only 1% of pediatric patients with solid tumor evaluated had CH involving myeloid genes. Conclusions: These findings demonstrate the clinical relevance of identifying molecular abnormalities in predicting development of t-MDS/AL and should guide the formation of intervention protocols to prevent this complication in high-risk pediatric patients.
Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts
Authors: Hirokazu Takami, Asmaa Elzawahry, Yasin Mamatjan, Shintaro Fukushima, Kohei Fukuoka, Tomonari Suzuki, Takaaki Yanagisawa, Yuko Matsushita, Taishi Nakamura, Kaishi Satomi, Shota Tanaka, Akitake Mukasa, Nobuhito Saito, Masayuki Kanamori, Toshihiro Kumabe, Teiji Tominaga, Keiichi Kobayashi, Motoo Nagane, Toshihiko Iuchi, Kaoru Tamura, Taketoshi Maehara, Kazuhiko Sugiyama, Koji Yoshimoto, Keiichi Sakai, Masahiro Nonaka, Akio Asai, Kiyotaka Yokogami, Hideo Takeshima, Yoshitaka Narita, Soichiro Shibui, Yoichi Nakazato, Natsuko Hama, Yasushi Totoki, Mamoru Kato, Tatsuhiro Shibata, Ryo Nishikawa, Masao Matsutani, Koichi Ichimura
Journal: Neuro-Oncology (2022)

CNS germ cell tumors (GCTs) predominantly develop in pediatric and young adult patients with variable responses to surgery, radiation, and chemotherapy. This study aimed to examine the complex and largely unknown pathogenesis of CNS GCTs.We used a combined transcriptomic and methylomic approach in 84 cases and conducted an integrative analysis of the normal cells undergoing embryogenesis and testicular GCTs.Genome-wide transcriptome analysis in CNS GCTs indicated that germinoma had a transcriptomic profile representative of primitive cells during early embryogenesis with high meiosis/mitosis potentials, while nongerminomatous GCTs (NGGCTs) had differentiated phenotypes oriented toward tissue formation and organogenesis. Co-analysis with the transcriptome of human embryonic cells revealed that germinomas had expression profiles similar to those of primordial germ cells, while the expression profiles of NGGCTs were similar to those of embryonic stem cells. Some germinoma cases were characterized by extensive immune-cell infiltration and high expression of cancer-testis antigens. NGGCTs had significantly higher immune-cell infiltration, characterized by immune-suppression phenotype. CNS and testicular GCTs (TGCTs) had similar mutational profiles; TGCTs showed enhanced copy number alterations. Methylation analysis clustered germinoma/seminoma and nongerminoma/nonseminoma separately. Germinoma and seminoma were co-categorized based on the degree of the tumor microenvironment balance.These results suggested that the pathophysiology of GCTs was less dependent on their site of origin and more dependent on the state of differentiation as well as on the tumor microenvironment balance. This study revealed distinct biological properties of GCTs, which will hopefully lead to future treatment development.